Cell Cycle

Items 151-200 of 387

per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. CDK2 inhibitor

    SU9516 is a potent, selective cdk2 inhibitor. It inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest.
  2. Aurora Kinase inhibitor

    SAR156497 is an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy with IC50 = 0.5 nM (Aurora A), 1 nM (Aurora B / incenp), 3 nM (Aurora C / incenp) respectively SAR156497 combines high in vitro potency with satisfactory metabolic stability and limited CYP3A4 and PDE3 inhibition.
  3. CDK inhibitor

    Voruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
  4. CDK4 inhibitor

    CA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
  5. PLK inhibitor

    SBE 13 HCl is a selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 μM for PLK1, PLK3 and PLK2 respectively).
  6. CDK inhibitor

    Palbociclib is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
  7. Rho inhibitor

    CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription.
  8. CDK1 inhibitor

    Ro 3306 is an ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively).
  9. GTPase Ral inhibitor

    BQU57, a derivative of RBC8, is a selective GTPase Ral inhibitor relative to the GTPases Ras and RhoA.
  10. G-quadruplex structures inhibitor

    360A is a strong affinity and selectivity inhibitor of G-quadruplex structures.
  11. G-quadruplex structures inhibitor

    360A is a strong affinity and selectivity inhibitor of G-quadruplex structures.
  12. CDK inhibitor

    AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM, less potent to CDK3 and little active to CDK7.
  13. Aurora B inhibitor

    AZD1152 is a pro-drug that rapidly undergoes phosphatase-mediated cleavage in serum to release barasertib-hQPA, a selective Aurora B kinase inhibitor that has shown preliminary activity in clinical studies of patients with acute myeloid leukemia (AML).
  14. Chk2 inhibitor

    CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM.
  15. CDK9 inhibitor

    CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
  16. ROCK Inhibitor

    Chroman 1 is a highly potent and selective ROCK II inhibitor.
  17. CDK2 Inhibitor

    CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
  18. ROCK inhibitor

    H-1152, an isoquinolinesulfonamide derivative, is a more specific, stronger and membrane-permeable inhibitor of Rho-kinase with a Ki value of 1.6 nM, but poor inhibitor of other serine/threonine kinases.
  19. ROCK inhibitor

    H-1152 dihydrochloride, an isoquinolinesulfonamide derivative, is a more specific, stronger and membrane-permeable inhibitor of Rho-kinase with a Ki value of 1.6 nM, but poor inhibitor of other serine/threonine kinases.
  20. ROCK inhibitor

    Hydroxyfasudil, metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator.
  21. ROCK inhibitor

    Hydroxyfasudil hydrochloride, metabolite of Fasudil, is a potent Rho-kinase inhibitor and vasodilator.
  22. ROCK activator

    Narciclasine is a Rho/Rho kinase/LIM kinase/cofilin signaling pathway activator.
  23. CDK inhibitor

    NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
  24. ROCK inhibitor

    ROCK inhibitor is a highly potent inhibitor of human ROCK-1 and ROCK-2 isoenzymes with IC50 values of 0.6 and 1.1 nM, respectively.
  25. ROCK2 Inhibitor

    SLx-2119 is a small molecule and selective inhibitor of ROCK2 with IC50 of 105 nM; > 200 fold selecivity over ROCK1(IC50 =24 uM).
  26. Bmi1/Ring1A inhibitor

    PRT 4165 is an inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1). It prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2alpha.
  27. Chk1 Inhibitor

    SB 218078 is an inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively)
  28. CDK inhibitor

    AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models.
  29. CDK inhibitor

    Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor. IC50 values are 4, 70, 35, 850 and 75 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.
  30. CHK1 inhibitor

    CCT244747 is a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor with potential anticancer activity,
  31. MEK/Aurora Inhibitor

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
  32. CDK inhibitor

    NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1.
  33. CDK9 inhibitor

    LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
  34. Wee1/Chk inhibitor

    PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
  35. ROCK inhibitor

    Ripasudil (K-115) is potent ROCK inhibitor with IC50 of 51 nM and 19 nM for ROCK1 and ROCK2, respectively, used for the treatment of glaucoma and ocular hypertension.
  36. CDK inhibitor

    K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
  37. ROCK inhibitor

    SAR407899 is a potent and selective Rho kinase inhibitor with promising antihypertensive activity.
  38. Rab7 activator

    ML-098 is an activator of the GTP-binding protein Rab7 (EC50 = 77.6 nM).
  39. CDK inhibitor

    Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 ,M.
  40. Aurora B inhibitor

    HOI-07 is a potently Aurora B kinase inhibitor.
  41. Ras-Net inhibitor

    XRP44X is a Ras-Net (Elk-3) pathway inhibitor (IC50 = 10-20 nM). Indirectly inhibits Net phosphorylation upstream of Erk1/2 activation.
  42. K-Ras inhibitor

    6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
  43. KSR/Ras inhibitor

    APS-2-79 HCl, small molecule that stabilizes the KSR (Kinase suppressor of Ras) inactive state and antagonizes oncogenic Ras signalling (IC50 value 120 nM against ATP-biotin probe-labelling of KSR2).
  44. LIMK2 inhibitor

    LX7101 is a pyrrolopyrimidine-based, topically-delivered inhibitor of LIM domain kinase 2 (LIMK2), a kinase associated with the regulation of intraocular pressure.
  45. KSR/Ras inhibitor

    APS-2-79 is an antagonist of MEK phosphorylation by RAF through direct binding of the KSR active site.
  46. Dyrk1B inhibitor

    Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68??48 nM and 22??8 nM respectively.
  47. BTK inhibitor

    LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
  48. MYC inhibitor

    KJ Pyr 9 is a novel small-molecule inhibitor of MYC, KJ-Pyr-9, from a Krhnke pyridine library.
  49. CDC7 inhibitor

    LY-3177833 is a potent and selective inhibitor of CDC7 (Cell Division Cycle 7-related Protein Kinase).

Items 151-200 of 387

per page
Set Descending Direction